Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Irinotecan Hydrochloride

FDA-approved product (injectable, injection), marketed as Camptosar, Irinotecan Hydrochloride, Onivyde.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Irinotecan Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenocarcinoma
  • Cancer
  • Carcinoma
  • Malignant Pancreatic Neoplasm
  • Neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Topoisomerase 1 (top1) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA70.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Irinotecan Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Irinotecan Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer

    NCT00033657 · start 2002-08-15

    Registered record
    Registry ID
    NCT00033657
    Conditions
    Esophageal Cancer; Gastric Cancer
    Interventions
    cisplatin; irinotecan hydrochloride; paclitaxel; conventional surgery; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-08-15
    Completion
    2009-10
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Cancer; Gastric Cancer
    Interventioncisplatin; irinotecan hydrochloride; paclitaxel; conventional surgery +1 more
    PhasePhase 2
    Registry statusCompleted

  • Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

    NCT00248482 · start 2002-02

    Registered record
    Registry ID
    NCT00248482
    Conditions
    Lung Cancer
    Interventions
    Cisplatin; Gleevec™; irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-02
    Completion
    2008-01
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    InterventionCisplatin; Gleevec™; irinotecan
    PhasePhase 2
    Registry statusCompleted

  • ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

    NCT00030524 · start 2002-01

    Registered record
    Registry ID
    NCT00030524
    Conditions
    Colorectal Cancer
    Interventions
    gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-01
    Completion
    2003-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventiongefitinib
    PhasePhase 2
    Registry statusCompleted

  • ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer

    NCT00026364 · start 2001-11

    Registered record
    Registry ID
    NCT00026364
    Conditions
    Colorectal Cancer
    Interventions
    fluorouracil; gefitinib; irinotecan hydrochloride; leucovorin calcium
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-11
    Completion
    Not recorded
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventionfluorouracil; gefitinib; irinotecan hydrochloride; leucovorin calcium
    PhasePhase 1
    Registry statusCompleted

  • Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer

    NCT00020917 · start 2001-02

    Registered record
    Registry ID
    NCT00020917
    Conditions
    Colorectal Cancer
    Interventions
    cetuximab; fluorouracil; irinotecan hydrochloride; leucovorin calcium
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-02
    Completion
    2004-02
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventioncetuximab; fluorouracil; irinotecan hydrochloride; leucovorin calcium
    PhasePhase 2
    Registry statusCompleted